Merrion Pharma Says Novo Nordisk Won’t Be Exercising Option

Merrion Pharmaceuticals Plc said it has been informed by its partner, Novo Nordisk A/S, that Novo will not be exercising an option described in the agreement announced by Merrion on Dec. 22. “Merrion will not meet its revenue targets for 2011,” it said.    Link to Statement:{NSN LTDEEY3HBS3K <GO>}

To contact the editor responsible for this story: Dara Doyle at ddoyle1@bloomberg.net

Press spacebar to pause and continue. Press esc to stop.

Bloomberg reserves the right to remove comments but is under no obligation to do so, or to explain individual moderation decisions.

Please enable JavaScript to view the comments powered by Disqus.